Additional clinical benefits of MR antagonists were reported in patients with left ventricular hypertrophy and hypertension (Pitt et al., 2003) and in patients with atrial fibrillation (Dabrowski et al., 2010; Fudim et al., 2018). This evidence concerns the gene NR3C2 and hypertensive disorder.